Toripalimab With Chemoradiotherapy for Locally Advanced Cervical Cancer
Tests adding toripalimab to chemoradiotherapy in adults with locally advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: Toripalimab Combined With Definitive CCRT for LACC Patients
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with newly diagnosed, untreated locally advanced squamous cell cancer of the cervix. It tests toripalimab added to chemoradiotherapy against chemoradiotherapy alone.
- Age
- More than 18 years old
- Sex
- Women only
- Disease stage
- Locally advanced squamous cell carcinoma of the cervix, FIGO 2018 stage IB3 to IVA, with no sign of distant spread
- Earlier treatment
- No earlier treatment for this cancer. No earlier or current PD-1 antibody treatment or other immunotherapy aimed at PD-1/PD-L1.
Main reasons for not taking part
- Previous immunodeficiency disorders
- Any condition the researchers think raises the risk of treatment
- Earlier or current PD-1 antibody or other PD-1/PD-L1 immunotherapy
- Major organ failure
Read by machine on 9 November 2026.
Where in China
- Ruijin hospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT06256224
- Record updated
- 24 April 2024
- Original description
Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy, patients with high-risk locally advanced disease or with recurrent/metastatic disease have a poor prognosis with standard treatments. Immunotherapies are a rational treatment for this HPV-driven cancer that commonly expresses programmed cell death ligand-1. Toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1, showed promising anti-tumor efficacy in multiple solid tumors. This randomised study is evaluating toripalimab combined with CCRT versus CCRT alone for treatment-naïve LACC.Read full original descriptionShow less
Toripalimab Combined With Definitive Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma Patients
Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy, patients with high-risk locally advanced disease or with recurrent/metastatic disease have a poor prognosis with standard treatments. Immunotherapies are a rational treatment for this HPV-driven cancer that commonly expresses programmed cell death ligand-1. Toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1, showed promising anti-tumor efficacy in multiple solid tumors. This randomised study is evaluating toripalimab combined with CCRT versus CCRT alone for treatment-naïve LACC.
Inclusion: more than 18 years old females; had newly diagnosed and previously untreated locally advanced squamous cell carcinoma of the uterine cervix; FIGO 2018 stage IB3 to IVA with no evidence of distant metastasis; ECOG PS 0-1 without major organ failure; signed informed consent voluntarily.
Exclusion: previously suffered from immunodeficiency disorders; Previously received or currently receiving other PD-1 antibody treatments or other immunotherapies targeting PD-1/PD-L1; had any condition that researchers believed to be associated with increased risk of treatment.